Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evaxion ASEVAX +0.65%52 Net Cash per Share is $0.50 as of Jun. 2026. GuruFocus rates EVAX with a GF Score™ of 52/100 and a GF Value™ of $3.34 (Fairly Valued). The stock has 1 warning sign investors should review. Among 764 Biotechnology companies, Evaxion AS ranks worse than 57.07% on this metric.
Evaxion AS (NAS:EVAX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Evaxion AS Net Cash per Share Related Terms
Evaxion AS Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Evaxion AS's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVAX vs DYAI, ATOS, PVCT: Net Cash per Share Comparison
For the Biotechnology subindustry, Evaxion AS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evaxion AS Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evaxion AS's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Evaxion AS's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Evaxion AS's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evaxion AS (EVAX) has a Net Cash per Share of $0.50 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #436 out of 764 companies in the Biotechnology industry, placing it in the top 57.1%.
Is Evaxion AS's Net Cash per Share too high?
Evaxion AS's current Net Cash per Share is $0.50. The Biotechnology industry median Net Cash per Share is 5.23. Evaxion AS's value of $0.50 is 90.4% below this industry median. Based on the distribution chart, Evaxion AS ranks #436 out of 764 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Evaxion AS has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's Net Cash per Share compare to DYAI and ATOS?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #436 out of 764 companies for Net Cash per Share. This places Evaxion AS in the lower half of its industry. The industry median Net Cash per Share is 5.23. Evaxion AS's value of $0.50 is 90.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.23, based on 764 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evaxion AS's current Net Cash per Share of $0.50 is 90.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Evaxion AS and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evaxion AS's current Net Cash per Share is $0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Based on GuruFocus' analysis, Evaxion AS (EVAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.34, compared to a current price of $3.13 — trading 6.3% below its estimated fair value. The current Net Cash per Share is $0.50 and 90.4% below the Biotechnology industry median of 5.23. Evaxion AS's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Evaxion AS (EVAX), the current Net Cash per Share is $0.50 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evaxion AS (EVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Evaxion AS stock appears to be undervalued.
The current stock price of $3.13 is trading 6.3% below its estimated GF Value™ of $3.34.
GuruFocus considers Evaxion AS to be Fairly Valued.
Key valuation signals for EVAX:
Net Cash per Share: $0.50
GF Value™: $3.34 vs. price of $3.13 (6.3% below fair value)
Industry Position: 90.4% below the Biotechnology median (#436 of 764)
No single metric tells the full story. See the EVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
52GF Score
Get the complete analysis for EVAX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVAX has been successfully added to your 
